UA101435C2 - Аналоги нейропептида y, которые содержат по меньшей мере одну замену на синтетическую аминокислоту - Google Patents
Аналоги нейропептида y, которые содержат по меньшей мере одну замену на синтетическую аминокислотуInfo
- Publication number
- UA101435C2 UA101435C2 UAA201111164A UAA201111164A UA101435C2 UA 101435 C2 UA101435 C2 UA 101435C2 UA A201111164 A UAA201111164 A UA A201111164A UA A201111164 A UAA201111164 A UA A201111164A UA 101435 C2 UA101435 C2 UA 101435C2
- Authority
- UA
- Ukraine
- Prior art keywords
- neuropeptide
- amino acid
- analogues
- acid substitution
- synthetic amino
- Prior art date
Links
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 title abstract 3
- 238000006467 substitution reaction Methods 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108050002826 Neuropeptide Y Receptor Proteins 0.000 abstract 1
- 102000012301 Neuropeptide Y receptor Human genes 0.000 abstract 1
- 102000009497 Neuropeptide Y1 receptors Human genes 0.000 abstract 1
- 108050000303 Neuropeptide Y1 receptors Proteins 0.000 abstract 1
- 102000029748 Neuropeptide Y2 receptor Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108010089579 neuropeptide Y2 receptor Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
Abstract
Данное изобретение касается новых аналогов нейропептида Y, фармацевтических композиций, которые содержат их, лекарственных форм, которые содержат их, а также способа лечения заболеваний или состояний, опосредованных связыванием рецептора нейропептида Y. Более конкретно, данное изобретение связано с новыми аналогами нейропептида Y, которые включают по меньшей мере одну аминокислотную замену на неприродную аминокислоту, такую как 4Нур, в положении 34, и селективно связываются с нейропептидным рецептором подтипа Y1 в сравнении с рецептором нейропептида подтипа Y2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20815109P | 2009-02-20 | 2009-02-20 | |
| PCT/US2010/000491 WO2010096186A1 (en) | 2009-02-20 | 2010-02-19 | Analogues of neuropeptide y having at least one synthetic amino acid substitution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA101435C2 true UA101435C2 (ru) | 2013-03-25 |
Family
ID=42634167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201111164A UA101435C2 (ru) | 2009-02-20 | 2010-02-19 | Аналоги нейропептида y, которые содержат по меньшей мере одну замену на синтетическую аминокислоту |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8440611B2 (ru) |
| EP (1) | EP2398485A4 (ru) |
| JP (1) | JP5480301B2 (ru) |
| KR (1) | KR101345253B1 (ru) |
| CN (1) | CN102325540B (ru) |
| AU (1) | AU2010216383B2 (ru) |
| CA (1) | CA2751636C (ru) |
| EA (1) | EA019498B1 (ru) |
| MX (1) | MX2011008776A (ru) |
| UA (1) | UA101435C2 (ru) |
| WO (1) | WO2010096186A1 (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102325545A (zh) * | 2009-02-20 | 2012-01-18 | 益普生制药股份有限公司 | 具有神经肽y受体结合化合物的细胞毒性缀合物 |
| WO2020109546A1 (en) | 2018-11-29 | 2020-06-04 | University Of Copenhagen | Treatment of cardiovascular diseases |
| CN111494606B (zh) * | 2020-04-24 | 2021-12-14 | 广州医科大学 | 神经肽y的新应用 |
| WO2025133085A1 (en) * | 2023-12-21 | 2025-06-26 | Pephexia Therapeutics Aps | Selective npy5r agonists with high chemical and metabolic stability |
| CN118240015B (zh) * | 2024-03-21 | 2025-03-21 | 中国科学院近代物理研究所 | 一种针对脑胶质瘤的靶向多肽及放射性示踪剂 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5026685A (en) | 1988-07-15 | 1991-06-25 | The Salk Institute For Biological Studies | NPY peptide analogs |
| US5328899A (en) * | 1988-07-15 | 1994-07-12 | The Salk Institute For Biological Studies | NPY peptide analogs |
| WO1995000161A1 (en) | 1993-06-18 | 1995-01-05 | University Of Cincinnati | Neuropeptide y antagonists and agonists |
| US7534866B2 (en) * | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US20050019841A1 (en) | 1999-05-14 | 2005-01-27 | Arbor Vita Corporation | Modulation of signaling pathways |
| US6511984B2 (en) | 2000-03-30 | 2003-01-28 | Pfizer Inc. | Neuropeptide Y antagonists |
| DE60035787T2 (de) | 2000-11-24 | 2008-04-30 | Jean-Claude Reubi | Neuropeptid-Y1-Rezeptor-bindende Verbindungen zur Behandlung und Diagnose von Krebserkrankungen |
| GB0217015D0 (en) * | 2002-07-23 | 2002-08-28 | Bioacta Ltd | Peptide 4 |
| WO2004066966A2 (en) * | 2003-01-17 | 2004-08-12 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Peptide yy analogs |
| WO2007039318A2 (en) | 2005-10-06 | 2007-04-12 | Bayer Schering Pharma Aktiengesellschaft | Neuropeptide y analogs |
-
2010
- 2010-02-19 JP JP2011551067A patent/JP5480301B2/ja not_active Expired - Fee Related
- 2010-02-19 MX MX2011008776A patent/MX2011008776A/es active IP Right Grant
- 2010-02-19 US US13/202,030 patent/US8440611B2/en not_active Expired - Fee Related
- 2010-02-19 AU AU2010216383A patent/AU2010216383B2/en not_active Ceased
- 2010-02-19 CN CN201080008613.XA patent/CN102325540B/zh not_active Expired - Fee Related
- 2010-02-19 WO PCT/US2010/000491 patent/WO2010096186A1/en not_active Ceased
- 2010-02-19 CA CA2751636A patent/CA2751636C/en not_active Expired - Fee Related
- 2010-02-19 UA UAA201111164A patent/UA101435C2/ru unknown
- 2010-02-19 EP EP10744070A patent/EP2398485A4/en not_active Withdrawn
- 2010-02-19 EA EA201171075A patent/EA019498B1/ru not_active IP Right Cessation
- 2010-02-19 KR KR1020117020922A patent/KR101345253B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8440611B2 (en) | 2013-05-14 |
| US20120040885A1 (en) | 2012-02-16 |
| EP2398485A1 (en) | 2011-12-28 |
| JP2012518637A (ja) | 2012-08-16 |
| JP5480301B2 (ja) | 2014-04-23 |
| AU2010216383A1 (en) | 2011-09-15 |
| WO2010096186A1 (en) | 2010-08-26 |
| CN102325540B (zh) | 2015-09-23 |
| EP2398485A4 (en) | 2013-01-09 |
| MX2011008776A (es) | 2011-10-24 |
| CA2751636C (en) | 2016-08-30 |
| EA201171075A1 (ru) | 2012-04-30 |
| CA2751636A1 (en) | 2010-08-26 |
| KR101345253B1 (ko) | 2013-12-31 |
| CN102325540A (zh) | 2012-01-18 |
| EA019498B1 (ru) | 2014-04-30 |
| AU2010216383B2 (en) | 2013-06-20 |
| KR20110125236A (ko) | 2011-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200612892A (en) | Novel compounds | |
| TN2010000140A1 (en) | Compositions and methods for use antibodies against sclerostin | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| EA201170624A1 (ru) | Изоникотинамидные антагонисты рецепторов орексинов | |
| UA103198C2 (en) | Squaramide derivatives as cxcr2 antagonists | |
| MX2012002366A (es) | Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina. | |
| IN2014DN01811A (ru) | ||
| MY155654A (en) | Antibodies against human angiopoietin 2 | |
| TW200630336A (en) | Novel compounds | |
| TN2009000398A1 (en) | 5,6-dihydro-1h-pyridin-2-one compounds | |
| MX339060B (es) | Formulaciones del factor viii. | |
| EA201001711A1 (ru) | Смесь связанного триптофана в составе пептидов и связанного триптофана в составе полипептидов | |
| TW200621313A (en) | Pharmaceutical compositions | |
| TW200621690A (en) | Novel compounds | |
| TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
| MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
| WO2010054286A3 (en) | Substituted hydroxyphenylamine compounds | |
| EP2528578A4 (en) | DENTAL COMPOSITION USING A CALCIUM SOURCE | |
| WO2011017132A3 (en) | Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration | |
| TN2009000447A1 (en) | An extented-release composition comprising a somatostatin derivative in microparticles | |
| EP2129672A4 (en) | ESTER AND CARBAMATE AZAADAMANTANE DERIVATIVES AND METHODS OF USE | |
| ATE530188T1 (de) | Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs | |
| UA101435C2 (ru) | Аналоги нейропептида y, которые содержат по меньшей мере одну замену на синтетическую аминокислоту | |
| TW200720260A (en) | Prokineticin 1 receptor antagonists | |
| TW200716566A (en) | Prokineticin 2 receptor antagonists |